The Drug, the Disease, and Why the Stakes Are Enormous
IgA nephropathy — IgAN — is a slow-motion catastrophe for roughly 25 people per million diagnosed worldwide each year. The immune system deposits abnormal antibodies in the kidney's tiny filters, triggering inflammation, protein leakage into urine, and an inexorable decline in kidney function. Up to half of patients with persistent protein in their urine progress to outright kidney failure within 10 to 20 years, often ending up on dialysis or awaiting a transplant. Until very recently, medicine could do little more than slow the bleeding. Now, a wave of targeted therapies is racing to change that — and Novartis's Vanrafia sits at the center of the most consequential regulatory moment in this space.
What Novartis Announced — and What the Numbers Actually Say
On February 13, 2026, Novartis released final results from its Phase III ALIGN trial — the longest follow-up period of any pivotal IgAN study to date, enrolling 340 patients over roughly 132 weeks of treatment. The headline figure: Vanrafia produced a difference of +2.39 mL/min/1.73m² in estimated glomerular filtration rate change versus placebo at Week 136, measured four weeks after stopping the drug.
The problem is the p-value: 0.057. The conventional threshold for statistical significance is p<0.05. Vanrafia missed it.
Novartis's rebuttal comes in two parts. First, at Week 132 — the actual end of treatment — the eGFR difference was +2.59 mL/min/1.73m² with a nominal p=0.039, which does cross the threshold. Second, results were consistent across multiple timepoints and in a prespecified exploratory cohort of 64 patients who were also taking SGLT2 inhibitors, a newer class of diabetes-origin drugs now considered foundational care for proteinuric kidney disease.
The Statistical Trap Buried in Plain Sight
The Week 132 result sounds cleaner — but Novartis itself labels it "nominal," a term of art meaning it was not adjusted for multiplicity across the study's many endpoints and timepoints. Running enough comparisons will eventually produce a p<0.05 by chance; the "nominal" label is the statistician's honest acknowledgment of that risk. It is supportive evidence. It is not confirmatory evidence.
The four-week washout design — measuring at Week 136 after stopping at Week 132 — was intended to demonstrate structural, durable kidney protection rather than a fleeting hemodynamic effect from the drug still being active. That is a rigorous, credible design choice. But it is double-edged: if stopping the drug triggers even a partial rebound in blood pressure or protein leakage, the treatment separation narrows, and a p=0.039 on-treatment result becomes a p=0.057 off-treatment miss. The gap between those two numbers is not noise — it is a signal worth watching when the full dataset is published.
The Regulatory Knife's Edge
This is not merely a scientific debate. Vanrafia already holds accelerated FDA approval — granted in 2025 based on its ability to reduce proteinuria, a surrogate marker. Critically, the FDA label explicitly states that it has not been established whether Vanrafia actually slows kidney function decline. The ALIGN long-term eGFR readout was supposed to be the confirmatory evidence that converts accelerated approval into traditional approval. A borderline miss at the confirmatory endpoint hands the FDA leverage: it can demand additional analyses, a new study, or accept the totality of evidence on negotiated terms. Novartis says it plans to submit for traditional approval in 2026 regardless.
Competitive Pressure Makes the Framing Wars More Urgent
Novartis is not operating in a vacuum. Sparsentan, a rival IgAN drug, already carries a labeled claim to slow kidney function decline — a critical commercial and regulatory distinction. In a market where nephrologists and payers compare label language word by word, the absence of that claim on Vanrafia's label is a tangible disadvantage. Every quarter the traditional approval is delayed, Sparsentan consolidates prescriber habits.
Novartis's strategic response is visible in the press release's emphasis on SGLT2 inhibitor compatibility. By positioning Vanrafia as an add-on layer to the SGLT2i backbone now embedded in standard care, Novartis is making a combinability argument rather than a head-to-head efficacy argument — a shrewd repositioning given where the science landed.
What Sophisticated Investors Should Be Demanding
The press release supplies a result. It does not supply a story. The story requires five things the public does not yet have. First, eGFR slope decomposition: separating the acute hemodynamic dip at treatment initiation from the chronic structural effect tells you whether the drug is truly modifying disease or just temporarily altering kidney perfusion. Second, hard renal outcome data: directional signals on 40% eGFR decline, dialysis initiation, and transplantation — even if underpowered — will determine whether regulators and payers treat this as disease-modifying therapy or an expensive supplement to existing care. Third, discontinuation and missing data analysis: borderline p-values are acutely sensitive to how dropout patients are handled; edema and anemia — both known class effects of ETA antagonists — can drive selective discontinuation that systematically biases results. Fourth, safety stratified by background therapy: fluid retention risk in patients already on SGLT2 inhibitors and RAS inhibitors requires granular AE breakdowns. Fifth, benefit-risk segmentation by patient profile: who specifically gains kidney-years from this drug, and who faces the hepatotoxicity, anemia, teratogenicity, and edema risks without proportionate benefit.
The Bottom Line
Vanrafia's ALIGN data is not a failure — but it is not a triumph either. The effect size, roughly 2.4 mL/min/1.73m², translates to potentially months to a few years of preserved kidney function in high-risk patients, which is meaningful in a disease with no cure. But the confirmatory endpoint missed, the backup p-value carries a multiplicity caveat, and the FDA label currently says the kidney-protection claim is unproven. Novartis is betting that regulators will accept the totality of evidence. That bet is reasonable — but it is a negotiation, not a foregone conclusion. For investors, the question is not whether Vanrafia works. It is whether it works well enough, proven rigorously enough, to command the label language and the market position Novartis needs before the IgAN treatment landscape consolidates around its competitors.
not investment advice